Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of MaxCyte Inc (NASDAQ: MXCT) was $1.55 for the day, up 1.97% from the previous closing price of $1.52. In other words, the price has increased by $1.97 from its previous closing price. On the day, 0.93 million shares were traded. MXCT stock price reached its highest trading level at $1.59 during the session, while it also had its lowest trading level at $1.5.
Ratios:
Our analysis of MXCT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.71 and its Current Ratio is at 12.39. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 25 ’25 when Hemrajani Rekha sold 10,684 shares for $2.09 per share. The transaction valued at 22,378 led to the insider holds 39,893 shares of the business.
Swirsky Douglas J bought 50,000 shares of MXCT for $64,500 on Aug 13 ’25. The CHIEF FINANCIAL OFFICER now owns 161,811 shares after completing the transaction at $1.29 per share. On Aug 13 ’25, another insider, Masoud Maher, who serves as the President and CEO of the company, bought 75,000 shares for $1.37 each. As a result, the insider paid 102,915 and bolstered with 175,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MXCT now has a Market Capitalization of 165240304 and an Enterprise Value of 57185304. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.62 while its Price-to-Book (P/B) ratio in mrq is 0.87. Its current Enterprise Value per Revenue stands at 1.599 whereas that against EBITDA is -1.163.
Stock Price History:
Over the past 52 weeks, MXCT has reached a high of $5.20, while it has fallen to a 52-week low of $1.26. The 50-Day Moving Average of the stock is -7.66%, while the 200-Day Moving Average is calculated to be -45.62%.
Shares Statistics:
MXCT traded an average of 786.10K shares per day over the past three months and 619100 shares per day over the past ten days. A total of 106.59M shares are outstanding, with a floating share count of 97.60M. Insiders hold about 8.45% of the company’s shares, while institutions hold 68.37% stake in the company. Shares short for MXCT as of 1756425600 were 3286616 with a Short Ratio of 4.18, compared to 1753920000 on 3531269. Therefore, it implies a Short% of Shares Outstanding of 3286616 and a Short% of Float of 3.1.
Earnings Estimates
The dynamic stock of MaxCyte Inc (MXCT) is currently being evaluated by a team of 4.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.08 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.36 and -$0.46 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$0.4, with 6.0 analysts recommending between -$0.33 and -$0.47.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $9M to a low estimate of $7.61M. As of the current estimate, MaxCyte Inc’s year-ago sales were $8.16MFor the next quarter, 6 analysts are estimating revenue of $9.03M. There is a high estimate of $9.5M for the next quarter, whereas the lowest estimate is $8.06M.
A total of 7 analysts have provided revenue estimates for MXCT’s current fiscal year. The highest revenue estimate was $37.4M, while the lowest revenue estimate was $34.57M, resulting in an average revenue estimate of $36.4M. In the same quarter a year ago, actual revenue was $38.63MBased on 7 analysts’ estimates, the company’s revenue will be $41.79M in the next fiscal year. The high estimate is $44.66M and the low estimate is $39.66M.
